Intel backs Mylan's anti-Fintiv SCOTUS stance
16-09-2021
Mylan, Edwards back NHK-Fintiv challenge
31-08-2021
Janssen sues Mylan to block generic of schizophrenia drug
29-09-2020
EPO revokes Copaxone patent, clears path for Mylan
17-09-2020
ricochet64 / Shutterstock.com
Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Mylan Laboratories, NHK-Fintive, PTAB, SCOTUS, USPTO
